07:15 AM EDT, 08/11/2025 (MT Newswires) -- Kymera Therapeutics ( KYMR ) reported a Q2 net loss Monday of $0.95 per diluted share, compared with a loss of $0.58 a year earlier.

Analysts polled by FactSet expected a loss of $0.89.

Collaboration revenue for the quarter ended June 30 was $11.5 million, compared with $25.7 million a year earlier.

Analysts polled by FactSet expected $22.2 million.

As of June 30, Kymera said it had $963.1 million in cash, cash equivalents and investments, which it expects to provide it with a cash runway into H2 2028.

Shares of the company were down more than 1% in recent premarket activity Monday.

Price: 40.01, Change: -0.61, Percent Change: -1.50